Zeeshan Ali, MD
Hematology & Oncology · Greenville, SCNPI 1962780536
Payments from drug & device makers
What this record shows
21 manufacturers reported payments, led by Incyte Corporation at 40.4% of the total. That places this record below the midpoint for hematology & oncology clinicians in SC, where the typical reported total is $4,020.
Across 32 payments — averaging $38.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$495
- GSK$113
- Gilead$94
- Genentech USA, Inc.$72
- Taiho Oncology, Inc.$52
- Bristol Myers Squibb$49
- plus $350 from 15 others
Across 48 payments — averaging $2797.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$67K
- Merck$47K
- Jazz Pharmaceuticals Inc.$20K
What the payments were for
- Food & beverage$59649%
- Education$62951%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 5 | $495 |
| GSK | 1 | $113 |
| Gilead | 1 | $94 |
| Genentech USA, Inc. | 1 | $72 |
| Taiho Oncology, Inc. | 3 | $52 |
| Bristol Myers Squibb | 3 | $49 |
| Beigene USA, Inc. | 1 | $41 |
| Adaptive Biotechnologies Corporation | 2 | $34 |
| Novartis | 1 | $33 |
| Merck | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Acrotech Biopharma Inc. | 1 | $23 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Sanofi | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Amgen | 1 | $19 |
| AstraZeneca | 1 | $18 |
| Seagen Inc. | 1 | $17 |
| Pfizer | 1 | $13 |
| Rigel Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OJJAARA$113
How this compares
$1,225 in reported general payments places this provider in the 20th percentile of 166 hematology & oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 36 | $485,251 |
| Abiraterone Acetate | 68 | $374,447 |
| RevlimidLenalidomide | 11 | $185,851 |
| ImbruvicaIbrutinib | 13 | $167,503 |
| EliquisApixaban | 83 | $62,958 |
| XareltoRivaroxaban | 17 | $17,532 |
| Ondansetron Hcl | 81 | $3,367 |
| Prochlorperazine Maleate | 64 | $2,229 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 56 | $710 |
| Oxycodone Hcl | 41 | $451 |
| Potassium Chloride | 45 | $358 |
| Ondansetron OdtOndansetron | 16 | $342 |
| Levothyroxine Sodium | 31 | $280 |
| Gabapentin | 12 | $270 |
| Famotidine | 21 | $270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $49 | $185,85111 claims |
| PfizerEliquis | $13 | $62,95883 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 166 hematology & oncology providers in South Carolina.
Other hematology & oncology in Greenville
- Suzanne FanningGreenville$927K
- Stephen DyarGreenville$413K
- Bhumika PatelGreenville$225K
- Joe StephensonGreenville$57K
- Elizabeth CullGreenville$16K
- Kevin KoehlerGreenville$10K
- Paige GanemGreenville$9K
- Vikas DemblaSpartanburg$568K
- Kashyap PatelRock Hill$379K
- Tondre BuckSpartanburg$366K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.